GLMD Latest Press Releases

-- January 30, 2026 --

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PRNewswire 4:15 PM

-- December 8, 2025 --

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting PRNewswire 8:30 AM

-- December 4, 2025 --

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH PRNewswire 8:30 AM

-- December 1, 2025 --

Galmed Issues CEO Letter to Shareholders PRNewswire 8:30 AM

-- November 26, 2025 --

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PRNewswire 8:30 AM

-- November 18, 2025 --

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PRNewswire 8:30 AM

-- November 17, 2025 --

Key Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets Open Globe Newswire 10:48 AM

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro PRNewswire 8:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software